Developments in Ki67 and other biomarkers for treatment decision making in breast cancer.
about
Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling indexDifferential expression patterns and clinical significance of estrogen receptor-α and β in papillary thyroid carcinoma.Heterogeneity of Diffusion-Weighted Imaging in Tumours and the Surrounding Stroma for Prediction of Ki-67 Proliferation Status in Breast CancerPathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional studyPartially Digested Adult Cardiac Extracellular Matrix Promotes Cardiomyocyte Proliferation In Vitro.Altered expression of estrogen receptor β2 is associated with different biological markers and clinicopathological factors in papillary thyroid cancerEvaluation of Tumor Cell Proliferation by Ki-67 Expression and Mitotic Count in Lymph Node Metastases from Breast Cancer.Detection of Phenotypic Alterations Using High-Content Analysis of Whole-Slide ImagesIncreased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancerPrognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.Biological effects of green tea capsule supplementation in pre-surgery postmenopausal breast cancer patients.Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indicationsMultifractal analysis of tumour microscopic images in the prediction of breast cancer chemotherapy response.Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 ring study.HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells.Enhanced expression of early mitotic inhibitor-1 predicts a poor prognosis in esophageal squamous cell carcinoma patients.Tumor apparent diffusion coefficient as an imaging biomarker to predict tumor aggressiveness in patients with estrogen-receptor-positive breast cancer.A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard.Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility.Pre-operative Endocrine Therapy.The Impact of Ki-67 on Immunostaining in Classification of Luminal Subtypes of breast Cancer.The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.DCE-MRI texture analysis with tumor subregion partitioning for predicting Ki-67 status of estrogen receptor-positive breast cancers.Exploring knowledge, attitudes and experience of genitourinary symptoms in women with early breast cancer on adjuvant endocrine therapy.[Determination of proliferation in breast cancer by immunohistochemical detection of Ki-67].
P2860
Q33717341-30DEEAB9-BDCF-43D8-9308-C6477EE369EEQ33726623-A2A35FDD-4E9C-490E-A5C9-3ACB81E64C54Q33767081-602D4932-F58F-483E-87B8-51DA4BCCD0EBQ34567461-79A239F1-59C4-42C8-A7EC-D7E6DE21106EQ35858522-2DAD71B7-0275-4D79-A224-0E263826DB5BQ35919319-FF43BDF9-DCD3-471B-8ADA-552F392BE504Q35949311-77689F6D-028E-4E05-A1F1-97C412CEDDEEQ36852426-5E1C435C-5F7F-4438-8B13-3396D272FA98Q36889647-3CBB053B-56DD-4F57-9965-8168EBF4F25EQ37350137-1B991923-7D08-4A40-8B85-389C3902DC64Q37389357-4BE3F1F6-1EE2-42FC-882E-BC2C9C00D23FQ37607746-29A7FDEC-EAE3-4AE1-ADF2-B3DE9117D0D0Q38384816-3369E03E-45F3-4A87-A5A0-BEAD1AE16BCEQ38395457-CA990FF6-FFA6-409C-B216-544455DCD5E6Q38710164-CE864C22-16F5-43C6-BAA7-2F6F1392ECDEQ38761750-657E5AF5-BD1B-46F5-BAE6-1C74267F7530Q38873275-59234B39-53BE-4D2C-84A9-CC34F93FB1C1Q42438922-497FB417-B862-410B-80B4-CCCDB32FFC2FQ44521334-EA75E022-48EC-4AD6-B44F-ED189A921FA0Q46143861-51635E70-AD8E-42E8-BB45-2029790B00DBQ46392750-0734E8CF-2DD4-4A38-936B-DD2CECE57A68Q47205521-5F1C5E4F-8FE1-435B-BE84-9CA16321CC60Q47270135-E1C52156-11FE-449B-A117-DF3DF25B9C67Q47558942-D1C1163B-2E38-45D0-A782-3E8AEE1C0A91Q54384996-BE377563-6235-408F-A7EF-5E97BBAA837A
P2860
Developments in Ki67 and other biomarkers for treatment decision making in breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Developments in Ki67 and other biomarkers for treatment decision making in breast cancer.
@en
Developments in Ki67 and other biomarkers for treatment decision making in breast cancer.
@nl
type
label
Developments in Ki67 and other biomarkers for treatment decision making in breast cancer.
@en
Developments in Ki67 and other biomarkers for treatment decision making in breast cancer.
@nl
prefLabel
Developments in Ki67 and other biomarkers for treatment decision making in breast cancer.
@en
Developments in Ki67 and other biomarkers for treatment decision making in breast cancer.
@nl
P2860
P356
P1433
P1476
Developments in Ki67 and other biomarkers for treatment decision making in breast cancer.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDS307
P478
23 Suppl 10
P577
2012-09-01T00:00:00Z